|
|
Medscape Education
The Atopic Dermatitis Learning Center: Riding the Next Wave
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects 5% to 30% of children and 1% to 10% of adults globally. It is characterized by recurrent eczematous lesions and intense itch and can have a severe impact on quality of life. Numerous agents that target the immunological mechanism of AD are under investigation in pediatric and adult patients. It is imperative that clinicians have the most recent data to provide optimal outcomes for their patients with AD.
|
|
IEC Statement on New COVID 19 Vaccines
IEC has issued a position statement on COVID 19 Vaccines and Atopic Dermatitis to address concerns about potential risks associated with these novel vaccinations.
|
Read the latest IEC article, published in Dermatitis.
Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey Drucker AM, Lam M, Flohr C, Thyssen JP, Kabashima K, Bissonnette R, Dlova NC, Aoki V, Chen M, Yu J, Zhu JW, Micieli R, Nosbaum A. Dermatitis. 2022 Feb 15. doi: 10.1097/DER.0000000000000845. Epub ahead of print. PMID: 35170524.
For all IEC publications, see our expanded list.
|
IEC Webcasts Available
Webcasts of IEC symposia on "Diagnosis and Management of Non-Atopic Forms of Dermatitis in Atopic Dermatitis Patients" are now available on-demand.
|
NEA Presents Eczema Expo 2020
The National Eczema Association will be holding its Eczema Expo 2020 virtually this year.
For further details, see https://nationaleczema.org/eczema-expo/ |
Coronavirus SECURE-AD Registry
SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion – Atopic Dermatitis; www.covidderm.org) is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in AD patients who have been Covid-19 infected or where such an infection has been strongly suspected.
|
IEC Statement on COVID 19
IEC would like to provide guidance on the use of systemic treatments for atopic dermatitis (AD; commonly called eczema) in the context of the COVID-19 pandemic, based on currently available pandemic and pharmacologic information.
|
|
|
|
|
<< first < Prev 1 2 3 Next > last >>
|
|
Page 2 of 3 |
